The study enrolls patients with post-progression tissue biopsy confirmed via central laboratory MET overexpression and/or MET amplification (IHC: 90% of tumor cells staining at 3+ intensity or FISH: ≥10 copies of the MET gene in tumor cells). Here, MET is linked to neoplasm.